131 results
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward
8-K
EX-1.1
SABS
SAB Biotherapeutics Inc
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
)No Litigation. Except as set forth in the Registration Statement or the Prospectus, there are no actions, suits or proceedings by or before any … is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental
424B5
SABS
SAB Biotherapeutics Inc
26 Jan 24
Prospectus supplement for primary offering
4:00pm
. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though
8-K
EX-99.1
hwq0elb3i2wsw
25 Jan 24
Other Events
5:00pm
8-K
rarc1ta
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
EX-99.1
s82ky3
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
EX-99.1
gcn ec802
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
py51mjoslsj9j
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
EX-99.1
vzch0ea uh
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
8-K
EX-10.1
87btcf szfe
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
8-K
EX-99.1
6vcbnz4
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
POS AM
ccikmn5c kqle
10 Jul 23
Prospectus update (post-effective amendment)
5:19pm
8-K
c0kg3a42ylwftsm fs
21 Jun 23
Regulation FD Disclosure
8:50am
8-K
EX-99.2
vfv679u8udcybasrago2
21 Jun 23
Regulation FD Disclosure
8:50am
8-K
oi6k38w m80f5x
14 Jun 23
Regulation FD Disclosure
8:53am